Quartz·2 min read·medium
Eli Lilly beat earnings and raised its forecast as weight loss drug sales surged
✦AI Summary
Eli Lilly reported strong financial results, driven by a 91% surge in revenue for its weight loss drugs Mounjaro and Zepbound. The company subsequently raised its full-year earnings forecast following these record-breaking sales.
Mounjaro revenue jumped 91% to $9.9 billion and Zepbound brought in $4.9 billion as the drugmaker beat Wall Street estimates
businesshealtheconomy
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in